Arrowhead Pharmaceuticals (ARWR) Operating Income Growth (3y) (2013 - 2026)
Arrowhead Pharmaceuticals (ARWR) Operating Income Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | 16.96% |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.39 Bn | 467.60 Bn | 1.35 Bn | 38.78% |
| 5 | Vertex Pharmaceuticals | 122.08 Bn | 114.83 Bn | 2.59 Bn | 13.47% |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn | -12.10% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.97 Bn | 50.78 Bn | 1.41 Bn | 69.02% |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn | 55.96% |
| 10 | Arrowhead Pharmaceuticals | 12.34 Bn | 10.56 Bn | - | -70.23% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -70.23% |
| Dec 31, 2025 | 43.72% |
| Sep 30, 2025 | 36.19% |
| Jun 30, 2025 | -31.44% |
| Mar 31, 2025 | 109.34% |
| Dec 31, 2024 | -36.60% |
| Sep 30, 2024 | -35.72% |
| Jun 30, 2024 | -76.81% |
| Mar 31, 2024 | -64.73% |
| Dec 31, 2023 | -78.39% |
| Sep 30, 2023 | -29.30% |
| Jun 30, 2023 | -86.06% |
| Mar 31, 2023 | 60.90% |
| Dec 31, 2022 | -105.53% |
| Sep 30, 2022 | -120.34% |
| Jun 30, 2022 | -50.58% |
| Mar 31, 2022 | 8.03% |
| Dec 31, 2021 | -98.19% |
| Sep 30, 2021 | -79.76% |
| Jun 30, 2021 | -26.03% |